The Effect of Environmental Pollution on Colorectal Cancer
Clinical Study of the Effect of Environmental Pollution on the Prognosis of Colorectal Cancer.
1 other identifier
observational
6,300
0 countries
N/A
Brief Summary
Colorectal cancer (CRC) is one of the most common malignancies worldwide, and its main risk factors include age, genetic factors, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), unhealthy diets (e.g., high-fat, low-fibre diets), obesity, physical inactivity, smoking, and excessive alcohol consumption. The relationship between environmental pollution and colorectal cancer has received increasing attention in recent years. Studies have shown that long-term exposure to fine particulate matter in the air, such as passive smoking, soot and oil smoke exposure, incense burning exposure, occupational exposure and outdoor work, PM2.5, PM10 and NO2 may increase the risk of colorectal cancer. These particulate matter can enter the lungs through breathing and trigger a chronic inflammatory response in the systemic system, thus increasing the risk of cancer development. This study intends to determine the extent of air pollution's impact on colorectal cancer prognosis by analysing survival data of colorectal cancer patients in regions with different pollution levels. As well as to investigate the association between air pollution levels and postoperative recurrence in colorectal cancer patients, looking for possible mechanisms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2010
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2024
CompletedFirst Submitted
Initial submission to the registry
November 12, 2024
CompletedFirst Posted
Study publicly available on registry
November 13, 2024
CompletedNovember 13, 2024
November 1, 2024
14.8 years
November 12, 2024
November 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
colorectal cancer
the time for diagnosing colorectal cancer
From 18 years old until the developing colorectal cancer, through study completion, an average of 5 year.
Study Arms (1)
the colorectal cancer group
patients diagnosed as colorectal cancer
Eligibility Criteria
patients diagnosed as colorectal cancer
You may qualify if:
- age ≥18 years;
- patients diagnosed with colorectal cancer by pathological biopsy before surgery;
- patients did not undergo chemotherapy, radiotherapy, targeted and immunotherapy, etc. before enrolment;
- willing to participate in this study and sign an informed consent form;
- complete clinical data.
You may not qualify if:
- patients with primary malignant tumours other than colorectal cancer;
- patients with systemic diseases, such as severe cardiopulmonary insufficiency, that affect the choice of treatment options;
- patients who are not suitable for enrolment as assessed by the investigator;
- incomplete clinical data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dong Penglead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 12, 2024
First Posted
November 13, 2024
Study Start
January 1, 2010
Primary Completion
November 1, 2024
Study Completion
November 1, 2024
Last Updated
November 13, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share
Clinical centres conducting this study are not allowed to disclose patient information and data sharing.